Greenwich LifeSciences (GLSI) Common Equity (2019 - 2026)

Greenwich LifeSciences (GLSI) has 7 years of Common Equity data on file, last reported at $353217.0 in Q4 2025.

• Quarterly Common Equity fell 61.13% year-over-year to $353217.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $353217.0 (down 61.13% YoY) and the FY2025 annual result came in at $353217.0, down 61.13% from the prior year.
• Common Equity retreated to $353217.0 in Q4 2025, from $2.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $29.7 million in Q1 2021 to a low of $353217.0 in Q4 2025.
• A 5-year average of $12.0 million and a median of $9.8 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2021 — Common Equity soared 2193.22% — and 2024, when it slumped 86.44%.
• Tracing GLSI's Common Equity over 5 years: stood at $26.8 million in 2021, then tumbled by 50.75% to $13.2 million in 2022, then slumped by 49.29% to $6.7 million in 2023, then plunged by 86.44% to $908626.0 in 2024, then tumbled by 61.13% to $353217.0 in 2025.
• The last three Common Equity figures came in at $353217.0 (Q4 2025), $2.2 million (Q3 2025), and $1.4 million (Q2 2025), per Business Quant data.